Castle Biosciences to Host Investor Day on Sept. 20, 2022
Castle’s Investor Day event is scheduled to begin at
To register for the virtual event, please visit the Events & Presentations section of the Company’s investor relations page (https://ir.castlebiosciences.com/overview/default.aspx). A replay of the webcast will be available on the Company’s website following the conclusion of the live broadcast.
About
Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20220824005090/en/
Investor Contact:
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: